Table 3 Correlation between clinicopathological characteristics and HDAC6 and PD-L1 expression.

From: Histone deacetylase 6 and programmed death ligand-1 expressions after neoadjuvant chemotherapy are upregulated in patients with ovarian high-grade serous carcinoma

Variables

HDAC6 (after NAC)

PD-L1 (after NAC)

Low

High

P value

Negative

Positive

P value

Age

 ≤ 60

25

9

0.320

29

5

0.532

 > 60

19

4

19

4

CA125 (U/mL)

 ≤ 1,000

21

2

0.035

20

3

0.468

 > 1,000

23

11

28

6

FIGO stage

 III

33

10

0.602

36

7

0.180

 IV

11

3

12

2

Surgical status

 R0

28

9

0.491

30

7

0.369

 R1

16

4

18

2

CRS (n = 54)

 1/2

19

6

0.622

24

1

0.042

 3

22

7

22

7

RESICT (n = 56)

 CR/PR

42

12

0.614

45

9

0.702

 SD/PD

2

0

2

0

KELIM score

 <1

16

4

0.491

17

3

0.612

 ≥1

28

9

31

6

Recurrence

 Yes

39

11

0.508

42

8

0.696

 No

5

2

6

1

Death

 Yes

24

8

0.452

27

5

0.624

 No

20

5

21

4

  1. NAC neoadjuvant chemotherapy, CRS chemotherapy response score, RESICT response evaluation criteria in solid tumours, CR complete response, PR partial response, SD stable disease, PD progressive disease, KELIM cancer antigen 125 ELIMination rate constant K, HDAC6 histone deacetylase 6, PD-L1 programmed death ligand-1, CA125 cancer antigen 125, FIGO international federation of gynecology and obstetrics.
Back to article page